Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter (REDUCE-HTN) - POST MARKET APPROVAL CLINICAL SURVEILLANCE STUDY

NCT01541865 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT01541865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01541865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter (REDUCE-HTN) - POST MARKET APPROVAL CLINICAL SURVEILLANCE STUDY
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Completed
Start date
February 29, 2012
Completion date
June 30, 2015
Enrollment
146 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension